Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3122 in advanced solid tumors
NCT07269145Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3122 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 3 more, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
TQB3122
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT07269145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269145.